173089-82-2

Basic information

• Product Name: METHYL ISOQUINOLINE-6-CARBOXYLATE
• Synonyms: METHYL ISOQUINOLINE-6-CARBOXYLATE;Isoquinoline-6-carboxylic acid methyl ester;6-Isoquinolinecarboxylic acid, methyl ester
• CAS NO: 173089-82-2
• Molecular Formula: C11H9NO2
• Molecular Weight: 187.19
• Mol File: 173089-82-2.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: METHYL ISOQUINOLINE-6-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL ISOQUINOLINE-6-CARBOXYLATE(173089-82-2)
• EPA Substance Registry System: METHYL ISOQUINOLINE-6-CARBOXYLATE(173089-82-2)

Safety Data

• Hazardous Substances Data: 173089-82-2(Hazardous Substances Data)

Usage

Uses

Methyl 6-Isoquinolinecarboxylate is a reagent in the synthesis of isoquinoline acids.

Upstream product

• 67-56-1 methanol 
• 106778-42-1 isoquinoline-6-carbonitrile 
• 34784-05-9 6-bromo-isoquinoline 
• 3375-31-3 palladium diacetate 
• 173089-81-1 6-isoquinoline carboxaldehyde 
• 201230-82-2 carbon monoxide 
• 106778-43-2 isoquinoline-6-carboxylic acid 
• 1078-30-4 quinoline-7-carboxylic acid 

Downstream Products

• 170097-66-2 3,4-Dihydro-1H-isoquinoline-2.6-dicarboxylic acid 2-tert-butyl ester-6-methyl ester 
• 170097-67-3 2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 173089-81-1 6-isoquinoline carboxaldehyde 
• 1637280-23-9 4-bromoisoquinoline-6-carboxylic acid 
• 185057-00-5 methyl 1,2,3,4-tetrahydroisoquinoline-6-carboxylate 
• 106778-43-2 isoquinoline-6-carboxylic acid 
• 188861-59-8 (isoquinolin-6-yl)methanol 

Relevant articles and documents

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation

Protein arginine methyltransferases 5 (PRMT5) represents an attractive drug target in epigenetic field for the treatment of leukemia and lymphoma. Here, a series of N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)amide derivatives targeting PRMT5 were designed with structure-based approach and synthesized. Among them, compound 46 showed potent and selective PRMT5 inhibition activity with an IC50 of 8.5 nM, which was approximately equivalent with the phase I clinical trial PRMT5 inhibitor GSK-3326595 (IC50 = 5.5 nM). Compound 46 also displayed pronounced anti-proliferative activity in MV4-11 cells (GI50 = 18 nM) and antitumor activity in MV4-11 mouse xenografts model. This molecule can serve as an excellent tool compound for probing the biological function of PRMT5.

CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Disclosed are a condensed ring derivative, and a preparation method, an intermediate, a pharmaceutical composition and a use thereof. The condensed ring derivative of the present invention has a significant inhibitive effect on URAT1, which can effectively alleviate or treat hyperuricemia and other related diseases.